These findings suggest that Lf-modified PSNPs represent a promising dual-targeting nanocarrier for glioma therapy, leveraging Lf and HA-mediated receptor interactions for enhanced brain uptake and glioma specificity. The gene discussed is LTF; the disease is central nervous system cancer.